Group items tagged

If angiogenesis controls cancer growth, what controls angiogenesis? Researchers at the University of Michigan and the University of South Florida believe that the copper status is critical to the function growth factors.

Age, stress, and poor nutrition can sap our immune system of its effectiveness. Influenza provides one example. During young adulthood, when the body can mount a robust immune response to this common virus, influenza is rarely fatal. Among the elderly, however, the virus is associated with significant rates of death and hospitalization (Nichol KL 2005). The impact of aging on the immune system is profound. As people age, a number of critical immune system components are reduced or slowed, including cellular response, response to vaccines, and antibody production. At the same time, susceptibilities to infection and cancer are increased. Some of this increased susceptibility to disease is linked to chronic inflammation, which is associated with many disorders of aging (Ershler WB et al 2000; Hamerman D 1999; Taaffe DR et al 2000).

Induction of ovarian cancer cell apoptosis by 1,25-dihydroxyvitamin D3 through the down-regulation of telomerase. Jiang F, Bao J, Li P, Nicosia SV, Bai W. J Biol Chem. 2004 Dec 17;279(51):53213-21. Epub 2004 Oct 12. PMID: 15485861 doi: 10.1074/jbc.M410395200 Overall, the study suggests that the down-regulation of telomerase activity by 1,25(OH)2VD3 and the resulting cell death are important components of the response of OCa cells to 1,25(OH)2VD3-induced growth suppression. Progressive shortening of telomere associated with cell divisions limits the life span of normal cells and eventually leads to senescence. To become immortal, human cancers including OCa are invariably associated with activation of mechanism that maintains telomere length. Approximately 85-90% of cancers show reactivation of telomerase. The present study shows that telomerase in OCa cells is down-regulated by 1,25(OH)2VD3. Down-regulation of telomerase is due to decreased stability of hTERT mRNA rather than VDRE-mediated transcriptional repression through the putative VDRE present in the regulatory region of the hTERT gene. It is known that the inhibition of telomerase may lead to a phenotypic lag during which cells would continue to divide until the point at which the telomeres became critically short. This phenomenon may explain why the apoptotic induction by 1,25(OH)2VD3 needs the treatment for more than 6 days. As mentioned in the results, no detectable shortening of telomeric repeats was observed in parental OVCAR3 cells after 9 days of treatment with 1,25(OH)2VD3 (Fig. 4D). This is likely due to the fact that the short telomere (about 3 kb) in OVCAR3 cells is very close to the minimal length required for survival and that cells with detectably shorter telomere may have been selected against apoptosis. It has been shown that transformed human cells enter crisis once the terminal restriction fragment of the telomere reaches a length of about 4 kb. This is insufficient to protect chro

In this video Dr. Ramakant Deshpande explaining the 6 Myths and facts of Lung cancer. Dr. Ramakant Deshpande MS; FICS; FAIS; DHA having experience of 31+ years and is a Chief of Thoracic Surgical Oncology, Asian Institute of Oncology. - Padmashree award by the President of India in 2014 - Lifetime Achievement Award at the Indian National Critical Care Society Annual Meet at Jaipur 2014 - Lifetime Achievement Award by Zee Maaza TV in 2019 - Senior of Robotic surgery at the Asian Cancer Institute - Established the Minimally Invasive method of Thoracoscopy - President of the Indian Society of Oncology - Director - Asian Cancer Institute - Ex Tata Memorial Doctor This video is under the "My Health My Right" Initiative of MedicoExperts - A Global Virtual Hospital. For inquiry Call/WhatsApp us at +91 9769516280 #Lungcancer​ #MyHealthMyRight​ #lunghealth​ #lungtreatment​ #lungcancermyths​ #lungcancerfacts​ #MedicoExperts​ #DrRamakantDeshpande​ #oncology​ #cancer

In this video, Dr. Ramakant Deshpande explaining How does doctor decide Lung cancer treatment for different stages of Lung cancer. Lung cancer and its adversities can be lethal, if remains undiagnosed or left untreated. A multidisciplinary approach can successfully eliminate the cancer from lungs and patient may resume normal life after recovery, says Dr. Ramakant Dehspande, Chief of Thoracic Surgical Oncology, Asian Institute of Oncology. Lung cancer There are different sizes and stages of lung cancer, which are treated differently. Broadly, specialists categorize various types of lung cancer into two basic forms Non-small cell lung cancer and small cell lung cancer. The staging of lung cancer helps in deciding the severity of the disease, course of treatment, and chances of survival. Detection of cancer at an early stage increases the chances of successful treatment and full recovery of the patient. A small legion located in one area is known as the first stage; a little larger tumor is called stage 2; spread within the lungs is called stage 3, and if it spread to other parts then termed as stage 4. Doctor Profile: Dr. Ramakant Deshpande MS; FICS; FAIS; DHA having experience of 31+ years and is a Chief of Thoracic Surgical Oncology, Asian Institute of Oncology. - Padmashree award by the President of India in 2014 - Lifetime Achievement Award at the Indian National Critical Care Society Annual Meet at Jaipur 2014 - Lifetime Achievement Award by Zee Maaza TV in 2019 - Senior of Robotic surgery at the Asian Cancer Institute - Established the Minimally Invasive method of Thoracoscopy - President of the Indian Society of Oncology - Director - Asian Cancer Institute - Ex Tata Memorial Doctor This video is under the "My Health My Right" Initiative of MedicoExperts - A Global Virtual Hospital. For Inquiry Call or WhatsApp us at +919769516280 #lungcancertreatment​ #MyHealthMyRight​ #lungcancer​ #lungcancerstages​ #MedicoExperts​ #lungcancertreatmen

Determining the best way of treating cancer remains highly controversial, even among mainstream oncologists. What may surprise the reader is the large number of documented therapies that have been overlooked by establishment medicine. The fundamental objective of this book is to encourage the expedient transfer of published scientific findings from the research bench to the clinical setting where the patient may benefit. This is the concept of translational medicine, which means translating knowledge from the laboratory side of medicine to the front lines of patient care. Physicians who practice translational medicine react uniquely when informed about a novel therapy. Their curiosity first motivates them to evaluate the new approach in order to reaffirm safety and efficacy in the context of treatment that is appropriate to the patient's condition. The dedicated translational physician uses novel therapeutics based on:

Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma. Devaraj K, Gillison ML, Wu TC. Crit Rev Oral Biol Med. 2003;14(5):345-62. Review. PMID: 14530303

An independent British medical watchdog says the first treatment proven to help people with the deadliest form of skin cancer is too expensive to be used by the U.K.'s health care system, a recommendation critics called a potential death sentence.